Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.32 |
| ▸ | PLAU | P00749 | 1/20 | 0.31 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.31 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.30 |
| ▸ | FEN1 | P39748 | 2/20 | 0.30 |
| ▸ | CNR1 | P21554 | 1/20 | 0.30 |
| ▸ | CNR2 | P34972 | 1/20 | 0.30 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.30 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.30 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.30 |
| ▸ | BACE1 | P56817 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL348409 | 1.00 | ALDH1A1 (0.32) | ALDH1A1TSHRTDP1ESR2PLAU | |
| SCHEMBL2548208 | 0.85 | ALDH1A1 (0.32) | ALDH1A1TSHRTDP1ESR2PLAU | |
| SCHEMBL28506719 | 0.82 | ALDH1A1 (0.35) | ALDH1A1TSHRTDP1ESR2PLAU | |
| SCHEMBL9960735 | 0.79 | GABRA1 (0.35) | ALDH1A1TSHRTDP1 | |
| SCHEMBL25258472 | 0.78 | FEN1 (0.40) | ALDH1A1TSHRTDP1ESR2ALOX5AP | |
| SCHEMBL18074251 | 0.78 | ALDH1A1 (0.32) | ALDH1A1TSHRTDP1ESR2PLAU | |
| SCHEMBL28882059 | 0.78 | ALDH1A1 (0.38) | ALDH1A1TSHRTDP1ESR2PLAU | |
| SCHEMBL6677589 | 0.78 | ALDH1A1 (0.38) | ALDH1A1TSHRTDP1ESR2PLAU | |
| SCHEMBL28099521 | 0.77 | DPP4 (0.33) | — | |
| SCHEMBL3692332 | 0.77 | CA2 (0.40) | ALDH1A1TSHRTDP1CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240407252-A1 | FLUORINATED TETRADENTATE PLATINUM (II) COMPLEX, ELECTRONIC DEVICE, EQUIPMENT AND APPLICATION THEREOF | ZHEJIANG UNIVERSITY OF TECHNOLOGY (CN) | 2024-12-05 | — | — | US | disclosed |
| EP-4467554-A1 | FLUORINATED TETRADENTATE PLATINUM (II) COMPLEX, ELECTRONIC DEVICE, EQUIPMENT AND APPLICATION THEREOF | Zhejiang University of Technology (CN) | 2024-11-27 | — | — | EP | disclosed |
| WO-2023098730-A1 | COMPOUND CONTAINING CYCLOALKYL OR HALOALKYL | 正大天晴药业集团股份有限公司 | 2023-06-08 | — | — | WO | disclosed |
| US-11591342-B2 | Heterocyclic compound, application thereof and pharmaceutical composition comprising same | Suzhou Sinovent Pharmaceuticals Co., Ltd. (CN) | 2023-02-28 | — | — | US | disclosed |
| WO-2023001069-A1 | MACROCYCLIC AMIDE COMPOUNDS AND APPLICATION THEREOF | 南京明德新药研发有限公司 | 2023-01-26 | — | — | WO | disclosed |
| WO-2022257961-A1 | BENZOHETEROCYCLIC COMPOUND FOR TREATING EP2 AND EP4 RECEPTOR-MEDIATED DISEASES | 武汉人福创新药物研发中心有限公司 | 2022-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11591342-B2 | Heterocyclic compound, application thereof and pharmaceutical composition comprising same | ENPP2, ATXN10, PCSK9 | ALDH1A1 3517/4885TSHR 2363/4885TDP1 1254/4885 |
| US-20240407252-A1 | FLUORINATED TETRADENTATE PLATINUM (II) COMPLEX, ELECTRONIC DEVICE, EQUIPMENT AND APPLICATION THEREOF | F10, F2, PUF60 | ALDH1A1 3365/4885TSHR 1476/4885TDP1 3065/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.